The Clinton Herald, Clinton, Iowa

Lifestyles

June 29, 2013

Fish-oil pills lure drugmakers though benefits remain unproven

Fish oil has been touted as useful for everything from growing hair to treating clinical depression. Now drug makers are stepping up their promotion of its benefits for treating heart disease.

AstraZeneca, Amarin and GlaxoSmithKline are betting the market for prescription fish-oil pills will follow the success of cholesterol-lowering drugs including Lipitor, once the world's best-selling medicine with revenue of $13 billion a year.

Heart disease remains the world's biggest killer, accounting for 30 percent of global deaths, even as statins and other treatments have become more widely used. Now that Lipitor and many other statins have cheaper, generic competitors, drugmakers are looking for new ways to tackle the array of conditions that can lead to heart disease, including coupling triglyceride treatments with existing cholesterol-lowering pills for a one-two punch.

 "The number of people with elevated triglyceride levels is rising rapidly across the world, due in part to the increasing prevalence of obesity and diabetes," AstraZeneca Chief Executive Officer Pascal Soriot said when he bought fish-oil pill maker Omthera Pharmaceuticals Inc. for $443 million last month. "There is a clear need for effective and convenient alternatives to some of the existing treatments."

Unlike capsules that can be bought in health-food stores, the drugmakers' products are available only with a prescription, are highly concentrated and undergo a several-step purification process approved by the U.S. Food and Drug Administration.

There's a hitch, however. Statins have been proven in studies to cut heart risk. The benefits of fish-oil pills are less certain. Though they target triglycerides, fatty substances in the blood that have been linked to a higher risk of heart attacks, little evidence exists that the pills prevent heart attacks.

"It's very unclear what role fatty acids play for cardiac patients," Mark Urman, a member of the American College of Cardiology Prevention Committee and practicing cardiologist at Cedars-Sinai Heart Institute, said in an interview. "The lab tests look better, but has it done the patient any good?"

Study results have been mixed. Japanese research on almost 19,000 people who took fish oil with a statin had a 19 percent lower risk of heart attacks, sudden cardiac death and other major coronary events, compared with those who took a statin alone.

A late-stage trial of Vascepa sponsored by Amarin found that it cut triglyceride levels by almost 22 percent at a 4-gram dose and 10 percent at a 2-gram dose without raising cholesterol levels in patients taking statins.

Other trials have shown little or no benefit. A study of more than 12,500 patients showed that a 1-gram daily dose of omega-3 fatty acids didn't prevent death or other cardiovascular events compared with placebo, according to an article in the New England Journal of Medicine in June 2012. And a review of data from 68,000 patients who took fish oil supplements over 24 years showed no reduction in risk of heart attack, stroke and death, the Journal of the American Medical Association said in September.

If cleared by regulators, AstraZeneca's Epanova would be the latest prescription pill to enter the market. It would bolster the London-based company's best-selling drug, a statin called Crestor, once it faces generic competition in 2016. While the drugmaker is still formulating its strategy, the Crestor sales team will pitch the product as an added benefit to the statin, said William Mongan, AstraZeneca's executive director of U.S. business development.

Amarin won U.S. approval to market Vascepa to people who have triglyceride levels of 500 milligrams per deciliter of blood or greater, a group of about 4 million people, according to the Dublin-based drugmaker. It's also seeking clearance to sell Vascepa for an additional 40 million people who have triglyceride levels between 200 milligrams and 500 milligrams, a "multi-billion dollar market opportunity."

Glaxo, whose Lovaza has brought in almost 2.5 billion pounds ($3.8 billion) in sales in the past five years, is more guarded about the market's prospects. In its 2012 annual report, the London-based drugmaker said the market had declined by 7 percent compared with 2011. Economic pressures have resulted in fewer doctor visits and reduced testing for conditions such as very high triglycerides that don't have any obvious symptoms, Glaxo said.

Without much evidence to support the claim that the pills cut heart risk, health-care purchasers remain skeptical of the benefits. Britain's medical spending watchdog, the National Institute for Health and Care Excellence, this month said it no longer recommends that heart attack survivors take fish-oil pills to prevent further heart attacks, citing their "minimal" benefit.

"It should be clear that they are not alternatives to statins," Cedars-Sinai's Urman said. He prescribes them predominately for patients who are in danger of developing pancreatitis, a painful inflammation of the pancreas caused by elevated triglyceride levels.

Vascepa has a long way to go to catch Lovaza. The drug had $4.3 million in sales between January and the end of April compared with $424.6 million for Lovaza, according to Symphony Health, a U.S. consulting firm. Amarin had to hire its own sales force after failing to find either a buyer for the company or a partner to help market Vascepa.

Amarin has fallen 60 percent in the last year and closed yesterday at $5.68, giving the drugmaker a market value of $854 million.

Analysts predict Lovaza sales will decline about 1.4 percent this year, according to the average of eight estimates compiled by Bloomberg.

"Do we need more preparations on the market? No," said Robert Eckel, director of the lipid clinic at the University of Colorado Hospital at the Anschutz Medical Campus in Aurora, Colo., and past president of the American Heart Association. "Do we have all of the answers about whether they are beneficial or not? No, we don't have those yet."

 

1
Text Only
Lifestyles
  • Friend of the Fair Two honored as 'Friends' MORRISON, Ill. — The Whiteside County Fair recently announced its 2014 Friend of the Fair. Paul Vock and Dan Heusinkveld are this year’s honorees. The two men have been involved with the fair for decades.Vock started with the fair in 1971 as the Heav

    July 22, 2014 1 Photo

  • The Clinton Herald Jim Miller Low-cost, free cellphone options for seniors DEAR SAVVY SENIOR: What are the cheapest cell phone options available today to seniors living on a shoestring budget? I only need it for occasional calls. — Seldom Calling SeniorDEAR SELDOM: For financially challenged seniors who only want a cell pho

    July 19, 2014 1 Photo

  • Bice Nurses earn Daisy awards

    CLINTON — Two Clinton nurses recently earned Daisy awards.Mercy Medical Center nurses Jodie Atkinson and Kristen Bice earned the awards that is rewarded to extraordinary nurses. Atkinson began her career in nursing at Mercy Medical Center in 1995 on

    July 22, 2014 2 Photos

  • Revolver goes for $400 at auction CLINTON — Selling in two locations on June 21 proved to be a winner. I was selling in the first location with my son Jon and we had a strong bidding crowd. The second location had Jeff Lohr and Bill McWilliams holding firm with a nice crowd of bidder

    July 19, 2014

  • Sawmill New event cruises into Clinton CLINTON — Three Gateway-area locations are joining together in August for a river heritage event.The event will be held Aug. 3 and will feature a Blue Heron river cruise, a Sawmill Museum tour and a de Immigrant Windmill tour in Fulton, Illinois. The

    July 18, 2014 3 Photos

  • Minnick Ashford director appointed to commission CLINTON —The Ashford University campus director has been appointed to a volunteer commission.Charlie Minnick, vice president/campus director of Ashford University, has been appointed by Iowa Gov. Terry Branstad to the Iowa Commission on Volunteer Ser

    July 18, 2014 1 Photo

  • Summer lunch menus (July 21 to 25)

    Summer lunch menus at Jefferson and Bluff Elementary Schools, and Generations Area Agency on Aging

    July 17, 2014

  • Ax throw, log climb at Adirondack lumberjack class PAUL SMITHS, N.Y. — Ax throwing is encouraged in lumberjack class. It’s also OK to dump your classmate in the lake — as long as you’re both frantically trying to stay upright on a floating log.The annual Adirondack Woodsmen’s School is being held thi

    July 17, 2014

  • Locally-grown foods look to bigger business

    Once a niche business, locally grown foods aren't just for farmers markets anymore.

    July 16, 2014

  • What happens to your online accounts when you die?

    You've probably decided who gets the house or that family heirloom up in the attic when you die. But what about your email account and all those photos stored online?

    July 16, 2014

Front page
Clinton Herald Photos


Browse, buy and submit pictures with our photo site.

Poll

Should the city of Clinton appeal the open records violation ruling that will cost taxpayers $40,600?

Yes
No
     View Results
AP Video
Olympics 2014
Featured Comment
Featured Ads
Blue Zones Project
Parade
Magazine

Click HERE to read all your Parade favorites including Hollywood Wire, Celebrity interviews and photo galleries, Food recipes and cooking tips, Games and lots more.